SCOPE: A scorecard for osteoporosis in Europe

The ScoreCard for Osteoporosis in Europe (SCOPE) aims to facilitate and promote health care policies that will help to ensure that all Europeans have access to the best diagnosis and treatment to reduce their risk of osteoporosis and fractures.

Components that are critical to achieving this goal include

  • government policy
  • access to assessment of risk
  • access to medications

The Scorecard allows Europeans to measure how well their country is able to access these elements through the publicly-funded healthcare systems and provides a benchmark to measure future progress. The Scorecard was prepared by and independent panel of experts (see below) and draws from the report: Osteoporosis in the European Union: Medical Management, Epidemiology and Economic Burden.


The ScoreCard was produced by an independent panel of experts:

  • Professor John A Kanis (Chair), Professor emeritus, University of Sheffield, UK; President, International Osteoporosis Foundation.
  • Dr. Frederik Borgström, LIME/MMC, Karolinska Institutet, Stockholm, Sweden
  • Professor Juliet Compston, University of Cambridge School of Clinical Medicine, Department of Medicine, Cambridge, UK
  • Professor Karsten Dreinhofer , Charité Universitätsmedizin Berlin and Medical Park Berlin Humboldtmühle
  • Dr. Ellen Nolte, Health and Healthcare policy program, RAND Europe, Cambridge, UK
  • Dr. Linus Jonsson, OptumInsight, Stockholm, Sweden
  • Professor Willem Lems, VU University Medical Centre, Amsterdam, The Netherlands
  • Professor Eugene V McCloskey, Osteoporosis Centre, Northern General Hospital, Sheffield, UK
  • Professor Rene Rizzoli, Rehabilitation and Geriatrics, Geneva University Hospitals, Geneva, Switzerland.
  • Judy Stenmark, International Osteoporosis Foundation, Nyon, Switzerland
  • Hildrun Sundseth, European Institute of Women’s Health

Overall findings

  • Facilities and access to testing for osteoporosis are far from adequate.
  • Access to treatment that can help prevent fractures varies markedly from country to country;
  • In some member states, individuals with osteoporosis are restricted from accessing effective treatment options.
  • Less than half of women at high risk of fracture are treated despite the high cost of fractures and the availability of affordable medications.

Action is required!